바이오스펙테이터

by Jongwon Jang

Expanding their biopharmaceutical CDO business followed by ImmuneOncia

▲26일 인천 송도 삼성바이오로직스 본사에서 김태한 삼성바이오로직스 대표, 양보기·권재현 지아이이노베이션 대표가 CDO 사업 협약식을 맺고 기념촬영을 하고 있다. 삼성바이오로직스 제공.

Samsung Biologics and domestic drug development venture GI Innovation signed a CDO contract.

According to the bio industry on April 27th, Samsung Biologics and GI Innovation held a business agreement ceremony on the 26th at Incheon Songdo Samsung Biologics headquarter. The two companies signed a CDO agreement at the ‘2018 BIO International Convention’ in Boston, USA earlier this month.

CDO is a total project from producing cell lines to developing biopharmaceuticals. Samsung Bio Logics has entered the CDO business last year, following consignment production (CMO). This provides one stop service from drug process development to consignment production. CMO companies such as Swiss Lonza and Boehringer Ingelheim of Germany are also having CDO business.

Samsung Biologics also signed a CDO contract with domestic drug development company ImmuneOncia in January. In addition, it is reported that they are considering additional CDO contracts with domestic and foreign companies.

GI Innovation is a company challenges to develop a new drug therapy through microbiome and protein drug combo platform technology 'μ + Biologics'. Their CSO Jang Myung Ho, a professor at Osaka University, from the Green Cross Institute of Biomedical Engineering, IBS, and Genexin, and Kwon Jae Hyun from Daewoo Securities, Theragenetex, Genexin have launched the company.

GI Innovation is in the process of non-clinical trial of GI 311, a drug candidiate for an allergy disease combined with microbiome and IgE trap protein, and is aiming to enter phase 1 clinical trial next year.